MaxCyte (NASDAQ:MXCT) just reported results for the second quarter of 2024.
- MaxCyte reported earnings per share of -9 cents. This was above the analyst estimate for EPS of -13 cents.
- The company reported revenue of $10.43 million.
- This was 31.68% better than the analyst estimate for revenue of $7.92 million.